| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Tahir, Haroon Elrasheid, et al.
(författare)
-
HPLC-DAD, GC-MS, UHPLC-Q-TOF/MS2, ICP-MS and FT-NIR combined with the chemometrics explain seasonal variation in Cassia senna L. leaves from the coast of Red Sea in Sudan
- 2023
-
Ingår i: South African Journal of Botany. - : Elsevier. - 0254-6299 .- 1727-9321. ; 163, s. 20-29
-
Tidskriftsartikel (refereegranskat)abstract
- Crops reveal considerable capability to regulate their phytochemicals and trace element contents to seasonal changes in temperature and rainfalls. In this study, we have measured the secondary metabolites, volatiles, and trace elements of Cassia senna L leaves collected from the Red Sea State, Sudan during winter 2018, summer 2019, and autumn 2020. Chemical profiles were evaluated by High-performance liquid chromatography with diode-array detection (HPLC-DAD), Ultra-high performance liquid chromatography (UHPLC); Inductively coupled plasma mass spectrometry(ICP-MS), Gas chromatography-mass spectrometry (GC-MS), Fourier-transform near-infrared spectroscopy (FT-NIR). 46 metabolites, 33 volatile compounds, and 13 elements were reported. The findings suggested significant seasonal variations in sennoside (A-B) compounds, which were reported to have positive health effects. In this study, aloesin was identified for the first time in senna leaves. Analysis of seasonal variations was obtained by principal component analysis and orthogonal partial least squares discriminant model. Additionally, chemical markers for each harvest season were reported. Overall, the number of metabolites and volatiles identified as a function of the season was autumn > summer> winter. Our results have enhanced the knowledge of the selection of harvesting time, with the best characteristics for the intended therapeutic application.(c) 2023 SAAB. Published by Elsevier B.V. All rights reserved.
|
|
| 5. |
- van Genuchten, C. M., et al.
(författare)
-
Heavy metal removal potential of olivine
- 2023
-
Ingår i: Water Research. - : Elsevier BV. - 0043-1354 .- 1879-2448. ; 245
-
Tidskriftsartikel (refereegranskat)abstract
- Industrial wastewater containing heavy metals, such as Cd and Pb, must be treated prior to discharge to meet increasingly stringent discharge guidelines and to limit the impact of toxic metals on ecosystems and human health. The application of olivine particles is a natural mineral-based solution to treat heavy metal-laden wastewaters, but little is known about the efficiency and mechanism of metal removal by this solid phase. In this work, we investigate the potential of olivine for heavy metal treatment by combining batch metal removal experiments with solid-phase characterization by synchrotron-based X-ray techniques and electron microscopy. We probed the removal behaviour of a variety of metal contaminants (Co, Ni, Cd, Zn, Cu, Pb; initial concentration = 1500 µg/L) and used Zn specifically to identify the metal removal pathway of olivine. We found that olivine in powdered (0.3 g/L) and granulated (0.5 g/L) forms was able to remove up to >90% of the initial metal, depending on the metal identity, with the efficiency increasing in order of Co ≤ Cd ≤ Ni
|
|
| 6. |
- Yulug, B., et al.
(författare)
-
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
- 2023
-
Ingår i: Translational Neurodegeneration. - : Springer Science and Business Media LLC. - 2047-9158. ; 12:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background Alzheimer's disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress.Methods Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients.Results We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment.Conclusion Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.
|
|
| 7. |
|
|
| 8. |
- Jovanović, Veljko, et al.
(författare)
-
The Satisfaction with Life Scale in Adolescent Samples : Measurement Invariance across 24 Countries and Regions, Age, and Gender
- 2022
-
Ingår i: Applied Research in Quality of Life. - : Springer Science and Business Media LLC. - 1871-2584 .- 1871-2576. ; 17:4, s. 2139-2161
-
Tidskriftsartikel (refereegranskat)abstract
- Measurement of adolescent life satisfaction across cultures has not received much attention in previous empirical research. The present study evaluated measurement invariance of the Satisfaction with Life Scale (SWLS) among adolescents in 24 countries and regions (N = 22,710; age range = 13–19 years; 53% female). A single-factor model with residual covariance between a pair of items tapping past life satisfaction fitted well in 19 countries and regions and showed a partial metric invariance. In a subset of nine countries and regions, partial scalar invariance was supported. Partial metric invariance across all 24 countries and regions was achieved when custom model modifications in five countries and regions were included. Three SWLS items showed evidence of noninvariance across cultures. The measurement model was found to operate similarly across gender and age. Our findings suggest that caution is needed when using the SWLS for measuring life satisfaction among adolescents from different cultures.
|
|
| 9. |
- Korenblik, R., et al.
(författare)
-
Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
- 2022
-
Ingår i: Cardiovascular and Interventional Radiology. - : Springer. - 0174-1551 .- 1432-086X. ; 45, s. 1391-1398
-
Tidskriftsartikel (refereegranskat)abstract
- Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR.
|
|
| 10. |
- Olson, Nathan D., et al.
(författare)
-
PrecisionFDA Truth Challenge V2: Calling variants from short and long reads in difficult-to-map regions
- 2022
-
Ingår i: Cell Genomics. - : Elsevier BV. - 2666-979X. ; 2:5, s. 1-12
-
Tidskriftsartikel (refereegranskat)abstract
- The precisionFDA Truth Challenge V2 aimed to assess the state of the art of variant calling in challenging genomic regions. Starting with FASTQs, 20 challenge participants applied their variant-calling pipelines and submitted 64 variant call sets for one or more sequencing technologies (Illumina, PacBio HiFi, and Oxford Nanopore Technologies). Submissions were evaluated following best practices for benchmarking small variants with updated Genome in a Bottle benchmark sets and genome stratifications. Challenge submissions included numerous innovative methods, with graph-based and machine learning methods scoring best for short-read and long-read datasets, respectively. With machine learning approaches, combining multiple sequencing technologies performed particularly well. Recent developments in sequencing and variant calling have enabled benchmarking variants in challenging genomic regions, paving the way for the identification of previously unknown clinically relevant variants.
|
|
